Advanced Search

Study Preview



Study Title and Description

Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
Author Wei L., Jia JD., Wang FS., Niu JQ., Zhao XM., Mu S., Liang LW., Wang Z., Hwang P., Robertson MN., Ingravallo P., Asante-Appiah E., Wei B., Evans B., Hanna GJ., Talwani R., Duan ZP., Zhdanov K., Cheng PN., Tanwandee T., Nguyen VK., Heo J., Isakov V., George J.
Country Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Beijing, China.
Year 2019
Numbers Pubmed ID: 30311701

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.